erlotinib hydrochloride has been researched along with salinomycin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (salinomycin) | Trials (salinomycin) | Recent Studies (post-2010) (salinomycin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 672 | 30 | 409 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | salinomycin (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.24 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JC; Chen, WC; Cheng, YT; Jian, YJ; Lin, YW; Peng, YS; Tung, CL; Wei, CL; Wu, CH; Zheng, HY | 1 |
1 other study(ies) available for erlotinib hydrochloride and salinomycin
| Article | Year |
|---|---|
Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrans; Thymidylate Synthase | 2017 |